Table 3.
n (%) | Not adherent at final, n (%) | Adherent at final, n (%) | P-value | |
---|---|---|---|---|
| ||||
Language of letter | 0.216b | |||
English | 362 (78.7) | 270 (74.6) | 92 (25.4) | |
Spanish | 98 (21.3) | 79 (80.6) | 19 (19.4) | |
Age | 0.676c | |||
Age, years | 70.0±10.5 | 70.1±10.7 | 69.6±9.9 | |
Gender | 0.784b | |||
Female | 231 (50.2) | 174 (75.3) | 57 (24.7) | |
Male | 229 (49.8) | 175 (76.4) | 54 (23.6) | |
Ethnicity | 0.602b | |||
White | 307 (66.7) | 232 (75.6) | 75 (24.4) | |
Hispanic | 66 (14.4) | 54 (81.8) | 12 (18.2) | |
African-American | 80 (17.4) | 58 (72.5) | 22 (27.5) | |
Asian | 7 (1.5) | 5 (71.4) | 2 (28.6) | |
Region | 0.576b | |||
Out of Texas | 16 (3.5) | 13 (81.3) | 3 (18.8) | |
West Texas | 221 (48.1) | 171 (77.4) | 50 (22.6) | |
East Texas | 223 (48.5) | 165 (74.0) | 58 (26.0) | |
Low Income subsidy eligibility | 0.575b | |||
No | 222 (48.3) | 171 (77.0) | 51 (23.0) | |
Yes | 238 (51.7) | 178 (74.8) | 60 (25.2) | |
Medication category | 0.223b | |||
Statin | 196 (42.6) | 141 (71.9) | 55 (28.1) | |
ACEI/ARB | 189 (41.1) | 150 (79.4) | 39 (20.6) | |
Oral antidiabetic | 75 (16.3) | 58 (77.3) | 17 (22.7) | |
Generic vs brand | 0.655b | |||
Generic | 431 (93.7) | 326 (75.6) | 105 (24.4) | |
Brand | 29 (6.3) | 23 (79.3) | 6 (20.7) | |
Day supply | 0.013b | |||
30 days or less | 170 (37.0) | 140 (82.4) | 30 (17.7) | |
>30 days | 290 (63.0) | 209 (72.1) | 81 (27.9) | |
Copay | 0.782c | |||
Copay, $ | 4.36±12.64 | 4.45±13.41 | 4.07±9.89 | |
Pharmacy type | 0.805b | |||
Retail | 449 (97.6) | 341 (76.0) | 108 (24.1) | |
Mail order | 11 (2.4) | 8 (72.7) | 3 (27.3) | |
Initial PDC | 0.013c | |||
PDC | 0.51±0.11 | 0.51±0.12 | 0.54±0.09 |
Notes:
Values represent mean ± SD for age, copay, and initial PDC.
Chi-squared test.
t-Test.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PDC, proportion of days covered.